Characterization of broad-spectrum mycobacterium abscessus class A β-lactamase

Journal of Antimicrobial Chemotherapy

Volumn 69, Issue 3, 2014, Pages 691-696

  Soroka, Daria ^a,b,c   Dubée, Vincent ^a,b,c   Soulier Escrihuela, Olivia ^a,b,c   Cuinet, Guillaume ^a,b,c   Hugonnet, Jean Emmanuel ^a,b,c   Gutmann, Laurent ^a,b,c,d   Mainardi, Jean Luc ^a,b,c,d   Arthur, Michel ^a,b,c  

^a INSERM   (France)

^b SORBONNE UNIVERSITÉ   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

Author keywords

lactams; Cefoxitin; Clavulanic acid; Mycobacterium tuberculosis

Indexed keywords

BETA LACTAMASE;

ANTIBIOTIC RESISTANCE; ENZYME SPECIFICITY; ENZYMOLOGY; HYDROLYSIS; KINETICS; METABOLISM; MYCOBACTERIUM;

BETA-LACTAM RESISTANCE; BETA-LACTAMASES; HYDROLYSIS; KINETICS; MYCOBACTERIUM; SUBSTRATE SPECIFICITY;

EID: 84894161480     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkt410     Document Type: Article

References (35)

1. Brown-Elliott BA, WallaceRJ Jr. Clinicalandtaxonomic status of pathogenic nonpigmented or late-pigmenting rapidly growing mycobacteria. Clin Microbiol Rev 2002; 15: 716-46.
2. Medjahed H, Gaillard JL, Reyrat JM. Mycobacterium abscessus: a new player in themycobacterial field. Trends Microbiol 2010; 18: 117-23.
3. Griffith DE, Aksamit T, Brown-Elliott BA et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med 2007; 175: 367-416.
4. Jarand J, Levin A, Zhang L et al. Clinical and microbiologic outcomes in patients receiving treatment for Mycobacterium abscessus pulmonary disease. Clin Infect Dis 2011; 52: 565-71.
5. Choi GE, Shin SJ, Won CJ et al. Macrolide treatment for Mycobacterium abscessus and Mycobacterium massiliense infection and inducible resistance. Am J Respir Crit Care Med 2012; 186: 917-25.
6. Nash KA, Brown-Elliott BA,Wallace RJ Jr. A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. Antimicrob Agents Chemother 2009; 53: 1367-76.
7. Nessar R, Cambau E, Reyrat JM et al. Mycobacterium abscessus: a new antibiotic nightmare. J Antimicrob Chemother 2012; 67: 810-8.
8. Philley JV, Griffith DE. Management of nontuberculous mycobacterial (NTM) lung disease. Semin Respir Crit Care Med 2013; 34: 135-42.
9. Huang YC, Liu MF, Shen GH et al. Clinical outcome of Mycobacterium abscessus infection and antimicrobial susceptibility testing. J Microbiol Immunol Infect 2010; 43: 401-6.
10. Jarlier V, Nikaido H. Permeability barrier to hydrophilic solutes in Mycobacterium chelonei. J Bacteriol 1990; 172: 1418-23.
11. Jarlier V, Gutmann L, Nikaido H. Interplay of cell wall barrier and b-lactamase activity determines high resistance to b-lactam antibiotics in Mycobacterium chelonae. Antimicrob Agents Chemother 1991; 35: 1937-9.
12. Thompson JS, Severson CD, Stearns NA et al. Immunological distinction ofmycobacterial b-lactamases. Infect Immun 1972; 5: 542-6.
13. Hackbarth CJ, Unsal I, Chambers HF. Cloning and sequence analysis of a class A b-lactamase from Mycobacterium tuberculosis H37Ra. Antimicrob Agents Chemother 1997; 41: 1182-5.
14. Galleni M, FranceschiniN,Quinting B et al. Use of the chromosomalclass A b-lactamase of Mycobacterium fortuitum D316 to study potentially poor substrates and inhibitory b-lactam compounds. Antimicrob Agents Chemother 1994; 38: 1608-14.
15. Basu D, Narayankumar DV, Van Beeumen J et al. Characterization of a b-lactamase from Mycobacterium smegmatis SN2. Biochem Mol Biol Int 1997; 43: 557-62.
16. KanedaS, Yabu K. Purificationandsomeproperties ofb-lactamasefrom Mycobacterium smegmatis. Microbiol Immunol 1983; 27: 191-3.
17. Hugonnet JE, Blanchard JS. Irreversible inhibition of the Mycobacterium tuberculosisb-lactamase byclavulanate. Biochemistry 2007;46: 11998-2004.
18. Sauvage E, Fonze E, Quinting B et al. Crystal structure of the Mycobacterium fortuitum class A b-lactamase: structural basis for broad substrate specificity. Antimicrob Agents Chemother 2006; 50: 2516-21.
19. Hugonnet JE, Tremblay LW, Boshoff HI et al. Meropenem-clavulanate is effective against extensively drug-resistant Mycobacterium tuberculosis. Science 2009; 323: 1215-8.
20. Mainardi JL, Hugonnet JE, Gutmann L et al. Fighting resistant tuberculosis with old compounds: the carbapenem paradigm. Clin Microbiol Infect 2011; 17: 1755-6.
21. Dooley KE,Obuku EA, Durakovic N et al.World HealthOrganizationgroup 5 drugs for the treatment of drug-resistant tuberculosis: unclear efficacy or untapped potential? J Infect Dis 2013; 207: 1352-8.
22. Ripoll F, Pasek S, Schenowitz C et al. Nonmycobacterial virulence genes in the genome of the emerging pathogen Mycobacterium abscessus. PLoS One 2009; 4: e5660.
23. Heydari H, Wee WY, Lokanathan N et al. MabsBase: a Mycobacterium abscessus genome and annotation database. PLoS One 2013; 8: e62443.
24. Moore M, Frerichs JB. An unusual acid-fast infection of the knee with subcutaneous, abscess-like lesions of the gluteal region; report of a case with a study of the organism, Mycobacterium abscessus, n. sp. J Invest Dermatol 1953; 20: 133-69.
25. Houben K, Marion D, Tarbouriech N et al. Interaction of the C-terminal domains of Sendai virus N and P proteins: comparison of polymerasenucleocapsid interactions within the paramyxovirus family. J Virol 2007; 81: 6807-16.
26. Clinical and Laboratory Standards Institute. Susceptibility Testing of Mycobacteria, Nocardiae, and Other Aerobic Actinomycetes-Second Edition: Approved Standard M24-A2. CLSI,Wayne, PA, USA, 2011.
27. Dubée V, Triboulet S, Mainardi JL et al. Inactivation of Mycobacterium tuberculosis L,D-transpeptidase LdtMt1 by carbapenems and cephalosporins. Antimicrob Agents Chemother 2012; 56: 4189-95.
28. Matagne A, Lamotte-Brasseur J, Dive G et al. Interactions between active-site-serine b-lactamases and compounds bearing a methoxy side chain on the a-face of the b-lactam ring: kinetic and molecular modelling studies. Biochem J 1993; 293: 607-11.
29. Fonzé E, Vanhove M, Dive G et al. Crystal structures of the Bacillus licheniformis BS3 class A b-lactamase and of the acyl-enzyme adduct formed with cefoxitin. Biochemistry 2002; 41: 1877-85.
30. Veziris N, Truffot C, Mainardi JL et al. Activity of carbapenems combined with clavulanate against murine tuberculosis. Antimicrob Agents Chemother 2011; 55: 2597-600.
31. England K, Boshoff HI, Arora K et al. Meropenem-clavulanic acid shows activity against Mycobacterium tuberculosis in vivo. Antimicrob Agents Chemother 2012; 56: 3384-7.
32. Dauby N, Muylle I, Mouchet F et al. Meropenem/clavulanate and linezolid treatment for extensively drug-resistant tuberculosis. Pediatr Infect Dis J 2011; 30: 812-3.
33. Payen MC, De Wit S, Martin C et al. Clinical use of the meropenemclavulanate combination for extensively drug-resistant tuberculosis. Int J Tuberc Lung Dis 2012; 16: 558-60.
34. Weiner JH, Bilous PT, Shaw GM et al. A novel and ubiquitous system for membrane targeting and secretion of cofactor-containing proteins. Cell 1998; 93: 93-101.
35. McDonough JA, McCann JR, Tekippe EM et al. Identification of functional Tat signal sequences in Mycobacterium tuberculosis proteins. J Bacteriol 2008; 190: 6428-38.